drugset / Trial / NCT01187810
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
NaSingle-groupOpen-labelTreatment
Summary
The purposee of this study is to determine the safety and dosing of Fenretinide when given continuously for 5 days, every 3 weeks, in pediatric patients with recurrent and/or resistant acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and non-Hodgkin's lymphoma (NHL).
Timeline
- Start
- 2010-08
- Primary completion
- 2018-04
- Completion
- 2018-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | fenretinide | Small molecule | 925 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | — | Intrathecal |
| Background | Methotrexate | Small molecule | — | Intrathecal |